US Bancorp DE Sells 44,950 Shares of Novo Nordisk A/S $NVO

US Bancorp DE lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 16.7% during the fourth quarter, HoldingsChannel reports. The firm owned 224,413 shares of the company’s stock after selling 44,950 shares during the period. US Bancorp DE’s holdings in Novo Nordisk A/S were worth $11,419,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the stock. Smith Chas P & Associates PA Cpas grew its position in Novo Nordisk A/S by 105.3% during the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after purchasing an additional 207,959 shares during the period. Clifford Swan Investment Counsel LLC grew its position in Novo Nordisk A/S by 13.7% during the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after purchasing an additional 37,453 shares during the period. Markel Group Inc. grew its position in Novo Nordisk A/S by 4.9% during the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after purchasing an additional 110,061 shares during the period. WCM Investment Management LLC grew its position in Novo Nordisk A/S by 3.7% during the 3rd quarter. WCM Investment Management LLC now owns 2,732,182 shares of the company’s stock worth $151,636,000 after purchasing an additional 97,477 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth about $3,171,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on NVO shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. CICC Research started coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target on the stock. Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Finally, Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA moves to restrict mass compounding of GLP‑1 active ingredients, which would make it harder for copycat/compounded alternatives to scale and should help protect branded pricing and volumes. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Novo will start shipping its oral Ozempic (semaglutide) tablets in the U.S. on May 4, expanding its addressable market beyond injectables and helping defend diabetes sales as pricing pressure mounts. Ozempic pill available in US
• Positive Sentiment: Distribution/access wins (WeightWatchers Med+ and GoodRx adding the Ozempic pill) should support uptake and patient access for the oral launch. WeightWatchers expands access to Ozempic pill
• Neutral Sentiment: Analysts’ consensus still shows material upside vs. the current price (average target ~$65.56) and small EPS estimate tweaks from Erste Group — supportive context but not immediate drivers. Analyst price targets
• Negative Sentiment: Canada approved a second generic semaglutide (Apotex), signaling increasing global generic competition that could undercut Novo’s pricing and margins in core markets over time. Canada approves second generic version of Ozempic
• Negative Sentiment: Eli Lilly’s Q1 beat, raised guidance and approval/rollout of Foundayo (an easier-to-take oral GLP‑1) widen competitive pressure on Novo’s weight‑loss franchise and could lead to share loss. Lilly’s Double-Beat Widens the GLP-1 Gap
• Negative Sentiment: Ongoing concerns around pricing pressure and margin compression in the GLP‑1 market could make NVO’s recent rebound vulnerable if generics and convenience-focused rivals keep gaining traction. Pricing pressure and falling margins analysis

Novo Nordisk A/S Trading Up 3.8%

NVO stock opened at $43.84 on Friday. The company’s 50-day simple moving average is $38.50 and its 200-day simple moving average is $47.26. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The firm has a market cap of $195.76 billion, a P/E ratio of 12.64, a PEG ratio of 10.42 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.34 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently announced a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were paid a dividend of $1.2751 per share. This represents a dividend yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 50.43%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.